Edoxaban tosylate monohydrate
Based on 9 publication(s) in Google Scholar
Edoxaban (DU-176b) monohydrate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Kis of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban monohydrate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban monohydrate can be used for preventing thromboembolic disease research.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.97%
- CAS 番号: 1229194-11-9
- 分子式: C31H40ClN7O8S2
- 分子量:738.27
-
保管条件:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-50667
Apixaban
-
HY-B0597
Fondaparinux sodium
-
HY-17567A
Heparin sodium salt
-
HY-17567C
Heparin sodium salt (MW 15kDa)
-
HY-109509
Enoxaparin
-
HY-B0385
Gabexate mesylate
-
HY-10264
Edoxaban
-
HY-50667R
Apixaban (Standard)
-
HY-50903
Rivaroxaban
-
HY-70035
Otamixaban
-
HY-10264R
Edoxaban (Standard)
-
HY-50903R
Rivaroxaban (Standard)
MedChemExpress（MCE）の使用を引用している文献 Edoxaban tosylate monohydrate
More- J Thromb Haemost. 2025 Jun;23(6):1938-1952. [Abstract]
- Molecules. 2023 Feb 28;28(5):2254. [Abstract]
- Thromb Res. 2021 Jan:197:141-143. [Abstract]
- PLoS One. 2024 May 15;19(5):e0292628. [Abstract]
- Virology. 2023 Aug:585:205-214. [Abstract]
- LabMed. 2024 Nov 18.
- SSRN. 2025 Dec 1.
- Authorea. 2023 Apr 17.
- Elife. 2022 Mar 23:11:e77444. [Abstract]
生物活性
IC50: 2.90 µM (platelet aggregation), Ki: 0.561 nM (free human FXa), 2.98 nM (prothrombinase), 0.715 nM (cynomolgus monkey FXa), 0.457 nM (rabbit FXa)[1]
Edoxaban monohydrate (1, 1 and 5 minutes respectively) prolongs PT, TT and APTT of human plasma in a concentration-dependent manner[1].
?
Edoxaban monohydrate inhibits thrombin-induced platelet aggregation, with an IC50 of 2.90 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human, rat, cynomolgus monkey and rabbit plasma; Human platelet
-
Concentration:
-
Incubation Time:1 and 5 minutes
-
Result:Antithrombin.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Slc: Wistar rats (210-240 g); Male New Zealand White rabbits(2.5-3.5 kg) (Both are venous stasis thrombosis model)[1].
-
Dosage:0.5, 2.5 and 12.5 mg/kg
-
Administration:Oral administration; once
-
Result:Inhibited exogenous FXa activity.
Antithrombotic.
化学情報
-
CAS 番号 1229194-11-9
-
性状 Solid
-
分子量 738.27
-
分子式 C31H40ClN7O8S2
-
Color White to off-white
-
SMILES
O=C(N(C)C)[C@@H](CC1)C[C@H]([C@H]1NC(C(NC(C=C2)=NC=C2Cl)=O)=O)NC(C3=NC(CC4)=C(CN4C)S3)=O.O=S(C5=CC=C(C)C=C5)(O)=O.O
-
別名
DU-176b monohydrate
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
J Thromb Haemost
2025 Jun;23(6):1938-1952. PMID: 40122463 -
Molecules
Generic Methods for Simultaneous Analysis of Four Direct Oral Anticoagulants in Human Plasma and Urine by Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry. [Abstract]2023 Feb 28;28(5):2254. PMID: 36903499 -
Thromb Res
Dielectric blood coagulometry as a means of evaluating the change in thrombin generation induced by direct oral anticoagulants. [Abstract]2021 Jan:197:141-143. PMID: 33217621 -
PLoS One
Xa inhibitor edoxaban ameliorates hepatic ischemia-reperfusion injury via PAR-2-ERK 1/2 pathway. [Abstract]2024 May 15;19(5):e0292628. PMID: 38748746 -
Virology
Structure-based virtual screening of ROCK1 inhibitors for the discovery of Enterovirus-A71 antivirals. [Abstract]2023 Aug:585:205-214. PMID: 37384967 -
-
-
-
Elife
2022 Mar 23:11:e77444. PMID: 35294338
溶剤 & 溶解度
DMSO : 50 mg/mL (67.73 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 1 mg/mL (1.35 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.39 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.39 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (280 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 1.3545 mL | 6.7726 mL | 13.5452 mL | 33.8629 mL |
| DMSO | 5 mM | 0.2709 mL | 1.3545 mL | 2.7090 mL | 6.7726 mL |
| 10 mM | 0.1355 mL | 0.6773 mL | 1.3545 mL | 3.3863 mL | |
| 15 mM | 0.0903 mL | 0.4515 mL | 0.9030 mL | 2.2575 mL | |
| 20 mM | 0.0677 mL | 0.3386 mL | 0.6773 mL | 1.6931 mL | |
| 25 mM | 0.0542 mL | 0.2709 mL | 0.5418 mL | 1.3545 mL | |
| 30 mM | 0.0452 mL | 0.2258 mL | 0.4515 mL | 1.1288 mL | |
| 40 mM | 0.0339 mL | 0.1693 mL | 0.3386 mL | 0.8466 mL | |
| 50 mM | 0.0271 mL | 0.1355 mL | 0.2709 mL | 0.6773 mL | |
| 60 mM | 0.0226 mL | 0.1129 mL | 0.2258 mL | 0.5644 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Edoxaban tosylate monohydrate 関連分類
HY-10264B 関連分類
Powered by Bioz